Whereas Congress has entrusted the Food and Drug Administration (FDA) with the safety of the United States people for more than 80 years; Whereas, on June 25, 1938, President Franklin D. Roosevelt signed the Federal Food, Drug, and Cosmetic Act (FFDCA) into law, authorizing the FDA to oversee, regulate, and approve new drugs; Whereas, on October 10, 1962, President John F. Kennedy signed the Kefauver-Harris Amendments to the FFDCA into law, charging the FDA with the authority to approve new drugs that were established by manufacturers to be proven safe and effective; Whereas, since the enactment of the FFDCA, the FDA has approved more than 19,000 prescription drug products for marketing; Whereas, on July 19, 1996, the FDA’s Reproductive Health Drugs Advisory Committee voted that mifepristone was safe for use and effective; Whereas, on September 28, 2000, the FDA approved the use of mifepristone for medical termination of pregnancy after a nearly 5-year review process; Whereas, in August 2008, an audit of the approval and oversight of mifepristone by the Government Accountability Office found that the approval of mifepristone was consistent with the approval and oversight of other drugs; Whereas mifepristone is used in more than half of abortion procedures nationwide; Whereas the safety and efficacy of medication abortion is supported by over two decades of scientific research and data collection; Whereas there is overwhelming evidence that medication abortion is safe and effective for virtually anyone who wants to end an early pregnancy, with a safety record of over 99 percent; Whereas more than 5,000,000 people in the United States have used mifepristone since its approval to safely end pregnancies at home and at health care centers, to safely treat miscarriages, and in other reproductive health care; Whereas access to mifepristone remains a lifeline for millions of Americans who seek reproductive health care